{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:41:08Z","timestamp":1773340868652,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.medcli.2010.11.032","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T08:50:39Z","timestamp":1309423839000},"page":"533-540","source":"Crossref","is-referenced-by-count":72,"title":["Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry"],"prefix":"10.1016","volume":"137","author":[{"given":"Mar\u00eda Jos\u00e9","family":"P\u00e9rez-Sola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Torre-Cisneros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"P\u00e9rez-Zafrilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Descalzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jes\u00fas","family":"G\u00f3mez-Reino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2010.11.032_bib0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2010.11.032_bib0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0025-6196(11)62405-1","article-title":"TNF-alpha inhibition: the need for a tumor necrosis factor thermostat","volume":"76","author":"O\u2019Dell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.medcli.2010.11.032_bib0015","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2010.11.032_bib0020","first-page":"471","article-title":"Current state of anti-tumor necrosis factor therapy in autoimmune diseases","volume":"131","author":"Sanchez Cano","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2010.11.032_bib0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","article-title":"Infections associated with tumor necrosis factor-alpha antagonists","volume":"84","author":"Crum","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medcli.2010.11.032_bib0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.bor.0000127594.92432.7c","article-title":"Infectious complications of treatment with biologic agents","volume":"16","author":"Hamilton","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.medcli.2010.11.032_bib0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2010.11.032_bib0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1157\/13116323","article-title":"Eficacia y seguridad de los tratamientos antagonistas del factor de necrosis tumoral en la artritis reumatoide","volume":"130","author":"P\u00e9rez Pamp\u00edn","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2010.11.032_bib0045","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0050","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0055","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0060","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.medcli.2010.11.032_bib0065","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.4049\/jimmunol.164.4.2016","article-title":"Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages","volume":"164","author":"Keane","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.medcli.2010.11.032_bib0070","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2010.11.032_bib0075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2010.11.032_bib0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection","volume":"36","author":"Furst","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0085","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jinf.2007.08.007","article-title":"Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients","volume":"55","author":"Salvana","year":"2007","journal-title":"J Infect"},{"key":"10.1016\/j.medcli.2010.11.032_bib0090","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0095","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0210","doi-asserted-by":"crossref","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Gonz\u00e1lez-Gonz\u00e1lez R. Registro espa\u00f1ol de acontecimientos adversos de terapias biol\u00f3gicas en enfermedades reum\u00e1ticas (BIOBADASER): informe de la situaci\u00f3n a 14 de enero de 2005. Reumatol Clin. 2005; 1:95-111.","DOI":"10.1016\/S1699-258X(05)72722-4"},{"key":"10.1016\/j.medcli.2010.11.032_bib0105","unstructured":"MedDRA Maintenance and Support Services Organization. Available from: www.meddramsso.org."},{"key":"10.1016\/j.medcli.2010.11.032_bib0110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","article-title":"CDC definitions for nosocomial infections, 1988","volume":"16","author":"Garner","year":"1988","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.medcli.2010.11.032_bib0115","unstructured":"International Conference on Harmonisation. Post approval safety data management: Note for guidance on definitions and standards for expedited reporting. Available from: www.emea.europa.eu\/pdfs\/human\/ich\/394503en.pdf."},{"key":"10.1016\/j.medcli.2010.11.032_bib0120","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0125","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2010.11.032_bib0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1157\/13080266","article-title":"Complicaciones infecciosas asociadas al uso de f\u00e1rmacos antagonistas del factor de necrosis tumoral. Revisi\u00f3n de conjunto","volume":"23","author":"Garc\u00eda-Lechuz","year":"2005","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.medcli.2010.11.032_bib0135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0140","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0150","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1579-2129(06)60222-X","article-title":"Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)","volume":"41","year":"2005","journal-title":"Arch Bronconeumol"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2010.11.032_bib0155","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2010.11.032_bib0160","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2010.11.032_bib0170","doi-asserted-by":"crossref","first-page":"ii62","DOI":"10.1136\/ard.61.suppl_2.ii62","article-title":"Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents","volume":"61","author":"Furst","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2010.11.032_bib0175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","article-title":"French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2010.11.032_bib0180","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1473-3099(03)00741-2","article-title":"Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection","volume":"3","author":"Tufariello","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medcli.2010.11.032_bib0185","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/01.CCM.0000117317.18092.E4","article-title":"Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock","volume":"32","author":"Dellinger","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medcli.2010.11.032_bib0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0195","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2010.11.032_bib0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.rhu.0000209881.43764.5f","article-title":"Relapsing oligoarticular septic arthritis during etanercept treatment of rheumatoid arthritis","volume":"12","author":"Mor","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.medcli.2010.11.032_bib0205","first-page":"2125","article-title":"Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment","volume":"32","author":"Bassetti","year":"2005","journal-title":"J Rheumatol"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775311001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775311001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T11:24:12Z","timestamp":1560338652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775311001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0025775311001539"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2010.11.032","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}